Modified antibody constant region
The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fcγ receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.
1. An IgG4 antibody comprising two polypeptides that are antibody heavy chains, each of which comprises an identical heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 3 with only the following amino acid changes:
(i) deletions of the amino acids at EU numbering positions 446 and 447;
(ii) optionally an amino acid substitution, relative to SEQ ID NO: 3, at one or more of the following EU numbering positions: 131, 133, 137, 138, 214, 217, 219, 220, 221, 222, 233, 234, 235 and 409; and
(iii) optionally a deletion of the amino acid at EU numbering position 236,
wherein the amino acid at EU numbering position 445 is not amidated and is at the C-terminus of each of the two polypeptides.
2. The IgG4 antibody of claim 1 , wherein the amino acids at EU numbering positions 233, 234, and 235 are substituted relative to the sequence of SEQ ID NO: 3, and the amino acid at EU numbering position 236 is deleted.
3. The IgG4 antibody of claim 1 , wherein the amino acids at EU numbering positions 131, 133, 137, 138, 214, 217, 219, 220, 221, and 222 are substituted relative to the sequence of SEQ ID NO: 3.
4. The IgG4 antibody of claim 1 , wherein the amino acid at EU numbering position 409 is substituted relative to the sequence of SEQ ID NO: 3.
5. The IgG4 antibody of claim 1 , wherein the amino acids at EU numbering positions 131, 133, 137, 138, 214, 217, 219, 220, 221, 222, 233, 234, 235, and 409 are substituted relative to the sequence of SEQ ID NO: 3, and the amino acid at EU numbering position 236 is deleted.
6. A pharmaceutical composition comprising the antibody of claim 1 .
7. An IgG4 antibody comprising two polypeptides that are antibody heavy chains, each of which comprises an identical heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 3 with only the following amino acid changes:
(i) deletions of the amino acids at EU numbering positions 446 and 447;
(ii) one or more substitutions relative to the sequence of SEQ ID NO: 3, including a substitution at one or more of the following EU numbering positions: 131, 133, 137, 138, 214, 217, 219, 220, 221, 222, 233, 234, 235 and 409; and
(iii) optionally a deletion of the amino acid at EU numbering position 236,
wherein the amino acid at EU numbering position 445 is the C-terminal amino acid of each of the two polypeptides and is not amidated.
8. The IgG4 antibody of claim 7 , wherein the amino acids at EU numbering positions 233, 234, and 235 are substituted relative to the sequence of SEQ ID NO: 3, and the amino acid at EU numbering position 236 is deleted.
9. The IgG4 antibody of claim 7 , wherein the amino acids at EU numbering positions 131, 133, 137, 138, 214, 217, 219, 220, 221, and 222 are substituted relative to the sequence of SEQ ID NO: 3.
10. The IgG4 antibody of claim 7 , wherein the amino acid at EU numbering position 409 is substituted relative to the sequence of SEQ ID NO: 3.
11. The IgG4 antibody of claim 7 , wherein the amino acids at EU numbering positions 131, 133, 137, 138, 214, 217, 219, 220, 221, 222, 233, 234, 235, and 409 are substituted relative to the sequence of SEQ ID NO: 3, and the amino acid at EU numbering position 236 is deleted.
12. A pharmaceutical composition comprising the antibody of claim 7 .
13. An IgG4 antibody comprising two polypeptides that are antibody heavy chains, each of which comprises an identical heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 3 with changes including:
deletions of the amino acids at EU numbering positions 446 and 447; and
(ii) at least one additional change at any of EU numbering positions 118-445 in the amino acid sequence of SEQ ID NO: 3, each additional change being independently selected from the group consisting of substitution, deletion, and insertion, wherein the at least one additional change includes a change selected from the group consisting of:
an amino acid substitution at EU numbering position 131,
an amino acid substitution at EU numbering position 133,
an amino acid substitution at EU numbering position 137,
an amino acid substitution at EU numbering position 138,
an amino acid substitution at EU numbering position 214,
an amino acid substitution at EU numbering position 217,
an amino acid substitution at EU numbering position 219,
an amino acid substitution at EU numbering position 220,
an amino acid substitution at EU numbering position 221,
an amino acid substitution at EU numbering position 222,
an amino acid substitution at EU numbering position 233,
an amino acid substitution at EU numbering position 234,
an amino acid substitution at EU numbering position 235,
an amino acid substitution at EU numbering position 409, and
a deletion of the amino acid at EU numbering position 236,
wherein the amino acid at EU numbering position 445 may be substituted but is not deleted, is the C-terminal amino acid of each of the two polypeptides, and is not amidated.
14. The IgG4 antibody of claim 13 , wherein the amino acids at EU numbering positions 233, 234, and 235 are substituted relative to the sequence of SEQ ID NO: 3, and the amino acid at EU numbering position 236 is deleted.
15. The IgG4 antibody of claim 13 , wherein the amino acids at EU numbering positions 131, 133, 137, 138, 214, 217, 219, 220, 221, and 222 are substituted relative to the sequence of SEQ ID NO: 3.
16. The IgG4 antibody of claim 13 , wherein the amino acid at EU numbering position 409 is substituted relative to the sequence of SEQ ID NO: 3.
17. The IgG4 antibody of claim 13 , wherein the amino acid at EU numbering position 236 is deleted.
18. A pharmaceutical composition comprising the antibody of claim 13 .
19. A method of producing an IgG4 antibody comprising two identical modified human IgG4 heavy chain constant regions with reduced C-terminal heterogeneity, the method comprising:
(a) preparing nucleic acid encoding the IgG4 antibody of claim 1 ;
(b) introducing the nucleic acid in a host cell;
(c) culturing the host cell to express the nucleic acid; and
(d) collecting the IgG4 antibody from the host cell,
wherein C-terminal heterogeneity of the IgG4 antibody in a composition comprising multiple copies of the IgG4 antibody is reduced compared to C-terminal heterogeneity in a composition comprising multiple copies of a naturally occurring human IgG4.
20. A method of producing an IgG4 antibody comprising two identical modified human IgG4 heavy chain constant regions with reduced C-terminal heterogeneity, the method comprising:
(a) preparing nucleic acid encoding the IgG4 antibody of claim 7 ;
(b) introducing the nucleic acid in a host cell;
(c) culturing the host cell to express the nucleic acid; and
(d) collecting the IgG4 antibody from the host cell,
wherein C-terminal heterogeneity of the IgG4 antibody in a composition comprising multiple copies of the IgG4 antibody is reduced compared to C-terminal heterogeneity in a composition comprising multiple copies of a naturally occurring human IgG4.
21. A method of producing an IgG4 antibody comprising two identical modified human IgG4 heavy chain constant regions with reduced C-terminal heterogeneity, the method comprising:
(a) preparing nucleic acid encoding the IgG4 antibody of claim 13 ;
(b) introducing the nucleic acid in a host cell;
(c) culturing the host cell to express the nucleic acid; and
(d) collecting the IgG4 antibody from the host cell,
wherein C-terminal heterogeneity of the IgG4 antibody in a composition comprising multiple copies of the IgG4 antibody is reduced compared to C-terminal heterogeneity in a composition comprising multiple copies of a naturally occurring human IgG4.